Combined biomarker for diagnosing atherosclerosis and application thereof
By analyzing the clinical biochemical indexes, intestinal microorganisms and plasma metabolites composition of patients with atherosclerosis, combined with machine learning algorithms, early diagnosis of atherosclerosis in the existing technology was solved. The problem of insufficient accuracy has achieved high accuracy early diagnosis and individualized treatment plans.
Patent Information
- Application Number
- CN202410876125.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2024-11-08
AI Technical Summary
The existing atherosclerosis diagnosis methods have high costs, invasive damage and early diagnosis difficulty. The existing biomarker detection methods are insufficiently accurate, making it difficult to identify atherosclerosis early.
By analyzing clinical biochemical indicators, intestinal microorganisms and plasma metabolites compositions of 208 atherosclerosis patients and 38 healthy controls, we selected the following: total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and glomerular filtration Combined biomarkers such as α-ketoglutaric acid, cholesterol sulfate, L-glutamic acid, TMAO, taurine, Alistipes, Collinsella, Clostridium_UCG-014, Streptococcus and Bacteroides, and developed to detect these markers The kit of the substance is combined with machine learning algorithms for early diagnosis.
The early accurate diagnosis of atherosclerosis was achieved, with an accuracy rate of 97.83%, providing individualized evaluation and treatment options for clinical practice, reducing the incidence and mortality of the disease.
Smart Images

Figure CN118914575A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a combined biomarker for diagnosing the occurrence of atherosclerosis and application thereof, belonging to the technical fields of laboratory medicine, clinical medicine, biotechnology and biochemistry. Background Art
[0002] Cardiovascular disease (CVD) is a general term for heart and blood vessel diseases, including atherosclerosis, coronary heart disease, hypertension, stroke, hyperlipidemia, and heart failure. Atherosclerosis (AS) is one of the main pathological manifestations of cardiovascular disease and one of the most studied diseases. The current diagnostic methods for atherosclerosis mainly rely on medical imaging and clinical manifestations, but there are certain limitations, such as high cost, invasive injury, and difficulty in early diagnosis. Coronary arteryangiography (CAG) is the gold standard for diagnosing atherosclerosis, but CAG is an invasive examination that may increase the risk of complications for certain high-risk populations. The development of AS is affected by multiple risk factors and occurs insidiously. CAG is only performed when clinical and biochemical indicators are abnormal and coronary artery lesions or malformations are suspected, and severe vascular lesions are often involved when clinically detected. Therefore, the identification of early AS is helpful for the prevention and treatment of the disease, thereby reducing morbidity and mortality. In recent years, multi-omics (16S rRNA sequencing of intestinal microorganisms and plasma metabolomics) combined analysis has been used to study biomarkers of disease occurrence and development, help predict the occurrence and prognosis of the disease, and guide the formulation of clinical treatment plans. Therefore, it is necessary to perform 16S rRNA sequencing and plasma metabolite composition analysis on patients with atherosclerosis to screen for combined biomarkers related to the occurrence and development of atherosclerosis, which is of great significance for the early diagnosis of atherosclerosis. Summary of the invention
[0003] First, the clinical biochemical indicators, intestinal microorganisms, and plasma metabolite composition of the discovery cohort of 208 patients with atherosclerosis and 38 healthy controls were analyzed to determine the key characteristics of patients with atherosclerosis and reveal the changes in intestinal microorganisms and plasma metabolites in patients with atherosclerosis. Through multi-omics data, joint biomarkers for the occurrence of atherosclerotic diseases were screened, and finally, the predictive accuracy of the biomarkers was verified in a validation cohort of 74 people.
[0004] The combined biomarkers include body mass index, total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, glomerular filtration rate, α-ketoglutaric acid, cholesterol sulfate, L-glutamate, TMAO, taurine, Alistipes, Collinsella, Clostridium_UCG-014, Streptococcus and Bacteroides. The combined prediction accuracy of these indicators for healthy and atherosclerotic patients can reach 97.83%, and AUC=0.987.
[0005] In the present invention, a group of biomarkers that can be used to detect atherosclerosis is provided, and further provided is the use of the biomarkers in preparing a kit for detecting atherosclerosis.
[0006] The first object of the present invention is to provide a group of biomarkers for detecting atherosclerosis, including plasma metabolites, intestinal microorganisms and clinical biochemical indicators.
[0007] In one embodiment of the present invention, the clinical biochemical indicators include total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and glomerular filtration rate; the plasma metabolites include α-ketoglutarate, cholesterol sulfate, L-glutamate, TMAO and taurine; and the intestinal microorganisms include Alistipes, Collinsella, Clostridium_UCG-014, Streptococcus and Bacteroides.
[0008] In one embodiment of the present invention, the biomarkers are derived from a blood sample and a stool sample of a subject.
[0009] In one embodiment of the present invention, the blood sample comprises plasma or serum.
[0010] The second object of the present invention is to provide a kit for detecting atherosclerosis, wherein the kit comprises the biomarker.
[0011] The present invention also provides use of the biomarker in preparing a kit, wherein the kit is used to determine whether a subject suffers from atherosclerosis.
[0012] In one embodiment of the present invention, the kit contains data samples of a known cohort.
[0013] In one embodiment of the present invention, the known cohort is subjects who are being determined to have atherosclerosis.
[0014] In one embodiment of the present invention, the kit contains reagents for detecting the biomarkers.
[0015] In one embodiment of the present invention, the reagent includes a substance for mass spectrometry detection of the biomarker.
[0016] In one embodiment of the present invention, determining whether a subject suffers from atherosclerosis comprises the following steps:
[0017] (1) determining the level of the biomarker in a sample from the subject;
[0018] (2) Inputting the levels of the biomarkers described in step (1) into a random forest model for discrimination.
[0019] In one embodiment of the present invention, in step (1), the plasma metabolites in the biomarkers are determined by mass spectrometry, and the intestinal microorganisms are determined by sequencing.
[0020] Beneficial effects:
[0021] 1. Combined with machine learning algorithms, this technology can extract key features from a large amount of biological data to achieve early diagnosis and individualized assessment of atherosclerosis. Key features include plasma metabolites, intestinal microorganisms and clinical biochemical indicators, among which clinical biochemical indicators include total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and glomerular filtration rate; plasma metabolites include α-ketoglutaric acid, cholesterol sulfate, L-glutamate, TMAO and taurine; intestinal microorganisms include Alistipes, Collinsella, Clostridium_UCG-014, Streptococcus and Bacteroides.
[0022] 2. This technology has high application value and can provide accurate diagnosis and individualized treatment plans for atherosclerosis in clinic, which is expected to reduce the morbidity and mortality of related diseases. The accuracy of detection using the atherosclerosis markers provided by the present invention is as high as 80% or more, which can be widely used in clinical auxiliary diagnosis or diagnosis of atherosclerosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The results of intestinal flora diversity analysis are shown in Figure 1. In the figure, a represents α diversity and b represents β diversity.
[0024] Figure 2 The composition of intestinal flora at the phylum and genus levels. In the figure, a is the phylum α level, and b is the genus level.
[0025] Figure 3 The results of differential analysis of intestinal flora in patients with different atherosclerosis. In the figure, a is the LDA score and b is the LEfSe branch diagram.
[0026] Figure 4 The changes in the top 30 intestinal microorganisms at the genus level. In the figure, a is the linear regression analysis, b is the difference in intestinal microorganisms between patients with different atherosclerosis, and c is the differential intestinal microorganisms.
[0027] Figure 5 The statistical analysis results of plasma metabolites are shown in Figure 1. a is the negative mode and b is the positive mode.
[0028] Figure 6 Figure 1 is the comparison result of plasma metabolites. Figure a is the Venn diagram of differential metabolites, and Figure b is the relative contents of 34 metabolites with significant differences between all AS groups and the healthy group.
[0029] Figure 7 The results of the random forest prediction of healthy and atherosclerotic patients. In the figure, a is single-omics, b is multi-omics, c is the AUC-ROC curve of the top 5 important variables of the plasma metabolome (P5) for predicting atherosclerosis, d is the AUC-ROC curve of the combination of the top 5 important variables of the plasma metabolome P(5) + the top 5 important clinical variables C(5) + the top 5 important intestinal flora variables G(5) for predicting atherosclerosis, and e is the 15 most accurate important variables. (C(all) clinical difference variables, P(all) plasma difference variables, G(all) intestinal flora difference variables; C(10) the top 10 important clinical difference variables, P(10) the top 10 important plasma difference variables, G(10) the top 10 important intestinal flora difference variables; C(5) the top 5 important clinical difference variables, P(5) the top 5 important plasma difference variables, G(5) the top 5 important intestinal flora difference variables).
[0030] Figure 8 Figure 3 ROC curves of combined biomarker analysis in the validation cohort. DETAILED DESCRIPTION
[0031] The present invention is further described in detail below with reference to specific embodiments, but the scope of protection claimed by the present invention is not limited to the scope described in the embodiments.
[0032] Example 1: Collection of research subject information
[0033] (I) Subjects
[0034] (1) Aged between 30 and 80, regardless of gender;
[0035] (2) Patients with atherosclerosis who were hospitalized in the Department of Cardiology, Wuxi People's Hospital and underwent coronary angiography from November 2019 to December 2021. The degree of vascular occlusion was assessed using the Gensini method. A stenosis of less than 25% was scored as 0 points, 26% to 50% as 2 points, 51% to 75% as 4 points, 76% to 90% as 8 points, 91% to 99% as 16 points, and complete occlusion as 32 points. The weight coefficients of different vessels were assigned as follows: left main trunk (5), proximal left anterior descending artery (2.5), middle left anterior descending artery (1.5), distal left anterior descending artery (1), first diagonal branch (1), second diagonal branch (0.5), proximal left circumflex artery (2.5), middle left circumflex artery (1.5), distal and posterior left circumflex artery (1), posterior lateral branch (0.5), posterior right coronary artery descending artery, distal, middle and proximal right coronary artery (1), and the cumulative score was calculated. According to the Gensini score, atherosclerotic patients who underwent coronary angiography (AS disease group) were divided into the following three groups: AS0 (Gensini score of 0 points), AS1 (Gensini score of 1-40 points) and AS2 (Gensini score>40 points). Healthy controls (Ctr) were healthy individuals with negative coronary angiography results and no other clinical signs and symptoms related to cardiovascular disease.
[0036] The exploratory experiment of this example was approved by Wuxi People's Hospital. Exclusion criteria include: (1) the subjects used probiotics, antibiotics or antimicrobial agents within 1 month; (2) had a history of alcoholism, or other diseases such as diabetes that affect intestinal flora; (3) had organic diseases of the digestive system, or had undergone digestive tract surgery; (4) heart failure, severe liver and kidney dysfunction, inflammatory bowel disease, autoimmune disease, or malignant tumors.
[0037] (II) Information Collection
[0038] (1) All subjects were fasted for 12 hours, and plasma and feces were collected in the morning of the next day. The subjects' morning fasting cubital vein blood samples (5-10 mL) were collected in purple anticoagulant tubes, centrifuged at 4000 rpm for 10 minutes at 4°C, and plasma was separated and stored in a -80°C refrigerator. Feces were collected using a fecal sampling box (a dry, clean, non-absorbent container with a lid), and the feces were placed in a sterile storage tube with a sterile collection spoon and stored in a -80°C refrigerator.
[0039] (2) Before coronary angiography, the name, age, sex, height, and weight of each subject were recorded. The systolic and diastolic blood pressures were measured on an empty stomach the next morning, and blood was drawn from the elbow vein. Clinical biochemical indices were measured, including triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting blood glucose, apolipoprotein A, apolipoprotein B, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transpeptidase, total protein, albumin / globulin, high-sensitivity C-reactive protein, lipoprotein A, D-dimer, glomerular filtration rate, fibrinogen, alkaline phosphatase, creatinine, total bilirubin, blood uric acid, and total white blood cell count.
[0040] Example 2: Comparison of clinical indicators in patients with atherosclerosis
[0041] Based on the Gensini score, all subjects were divided into four groups, including 38 healthy controls, 55 AS0 groups, 99 AS1 groups, and 54 AS2 groups. Table 1 shows the statistical table of clinical information of the subjects. Comparison showed that there were no significant differences in body mass index (BMI), systolic blood pressure, diastolic blood pressure, triglycerides, apolipoprotein A, fasting blood glucose, urea nitrogen, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, glutamyl transpeptidase, total protein, albumin / globulin, total bilirubin, and D-dimer among different groups. Compared with the healthy control, the AS group had significantly lower levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and glomerular filtration rate, and significantly higher clinical indicators including lipoprotein A, creatinine, uric acid, alkaline phosphatase, fasting blood glucose, total white blood cell count, and fibrinogen.
[0042] Table 1 Clinical information of subjects
[0043]
[0044]
[0045] Note: Data are expressed as mean ± standard deviation, p value indicates the difference between groups, p < 0.05 indicates that the difference is statistically significant, p < 0.01 indicates that the difference is significant, and p < 0.001 indicates that the difference is extremely significant.
[0046] Example 3: Composition of intestinal flora in patients with atherosclerosis
[0047] 1. Diversity of intestinal flora
[0048] Studies have shown that intestinal microorganisms play an important role in the occurrence and development of cardiovascular diseases. Intestinal microorganisms can affect human health through various effects, and changes in the composition of intestinal microorganisms are related to the occurrence and development of CVD. Therefore, the present invention performs 16S rRNA sequencing on the feces of patients with atherosclerosis and healthy controls to compare their intestinal microbial composition: the feces collected in Example 1 are processed using a fecal genomic DNA extraction kit to extract total DNA, and the amplicon library is subjected to high-throughput sequencing. Microbial diversity is analyzed through an online website (http: / / www.microbiomeanalyst.ca / ), and the online website (http: / / huttenhower.sph.harvard.edu / galaxy) analyzes the difference in communities between groups.
[0049] The results showed that there was no significant difference in the α diversity of intestinal flora between healthy controls and patients with atherosclerosis ( Figure 1 a). The distribution of different groups in the PCA graph is relatively concentrated, with no significant difference ( Figure 1 b). This indicates that there is no significant difference in the diversity, richness and composition of intestinal flora between patients with atherosclerosis and healthy controls.
[0050] 2. Composition and difference analysis of intestinal flora
[0051] Annotation of the intestinal flora at the phylum, class, order, and genus levels revealed that the intestinal flora of both healthy controls and patients with atherosclerosis was mainly composed of Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. There are large individual differences in the composition, diversity, and abundance of intestinal microorganisms. Firmicutes and Bacteroidetes are the dominant flora in healthy hosts, accounting for more than 90% of the total bacteria. The ratio of Firmicutes to Bacteroidetes is not the same in individuals, such as Figure 2 As shown, the abundance of Bacteroidetes in the intestine of healthy controls was higher than that of disease patients, while the abundance of Firmicutes was lower than that of disease patients.
[0052] Linear discriminant analysis (LEfSe) was performed on the intestinal flora to determine the microorganisms with significant differences between different groups. Figure 3 As shown in Figure 2, LEfSe analysis based on linear discriminant analysis (LDA) found that the control group was enriched with 12 significantly different genera, the AS0 group was enriched with 5 species, the AS1 group was enriched with 1 species, and the AS2 group was enriched with 8 species ( Figure 3a). In the control group, Bifidobacterium and Bacteroides were more abundant, in the AS0 group, Lactobacillus was more abundant, in the AS1 group, Veillonella was more abundant, and in the AS2 group, Streptococcus was more abundant.
[0053] Then, the present invention analyzed the fold changes of the top 30 intestinal microorganisms in abundance at the genus level between the disease group and the healthy control group, and performed linear regression analysis on these significantly changed intestinal microorganisms between different AS groups. Figure 4 As shown in a, there was a strong positive correlation between the AS0 and AS1 groups, the AS0 and AS2 groups, and the AS1 and AS2 groups, indicating that when atherosclerosis develops seriously, some intestinal microorganisms undergo the same changes. Compared with the healthy control group, the abundance of Lactobacillus, Streptococcus, Veillonella, and Haemophilus in the AS group increased significantly, and the abundance of Bacteroides and Bifidobacterium decreased significantly ( Figure 4 b). Veillonella and Haemophilus cause inflammatory responses by producing lipopolysaccharides, which are associated with various inflammatory markers in CVD risk and are elevated in patients with heart disease and atherosclerosis. Bifidobacterium is a beneficial microorganism in the intestine, and its relative abundance can serve as a marker of health. It is noteworthy that the relative abundance of Streptococcus and Haemophilus in the intestine increases significantly with the progression of the disease.
[0054] Example 4. Characteristics of plasma metabolites in patients with atherosclerosis
[0055] Treatment of plasma samples: Take 20 μL of plasma sample, add 4 volumes (80 μL) of ice methanol (containing 5 μg / mL Fmoc-glycine-15N as internal standard), vortex mix for 30 seconds to precipitate plasma proteins, centrifuge at 14000 rpm, 4°C for 10 minutes, centrifuge the supernatant again under the same conditions, and collect the supernatant for UPLC / QTOF-MS analysis.
[0056] UPLC / QTOF-MS detection conditions: The separation of plasma samples was carried out on a BEHAmide (100 mm×2.1 mm, 1.7 μm, Waters) column. Mobile phase A was 10 mmol / L ammonium formate in water, and mobile phase B was 10 mmol / L ammonium formate in 90% acetonitrile / 10% water. The elution program was as follows: 0-1 min, 100% B; 1-11 min, 100%-70% B; 11-12.5 min, 70% B; 12.5-13 min, 70%-100% B; 13-15 min, 100% B. Column temperature: 35°C; flow rate: 0.3 mL / min; injection volume: 2 μL.
[0057] Mass spectrometry conditions: electrospray ionization source (ESI), information was collected in positive and negative ion modes, the scanning range of plasma mass spectrometry was 50-1000 m / z, and the scanning range of fecal mass spectrometry was 100-1000 m / z. Capillary voltage was 4.5 kV, capillary temperature was 500 °C, cone voltage was 60 V, and nebulizer gas and auxiliary gas were both 50 Psi.
[0058] Data processing: The metabolomics results were collected as *.wiff files and then converted to *.mzXML files using MSConvert software. All MS data were aligned and standardized using MZmine 2.53 and Microsoft Excel 2020 to generate a peak table. The peak table was then uploaded to MetDNA for metabolite identification. SIMCA software was used for principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) to evaluate the reliability of the model. Differential metabolites were screened based on variable importance in projection (VIP) ranking and p-value (VIP>1, p<0.05), and the fold change (FC) of the relative expression of the differential metabolites between the two groups was calculated.
[0059] SIMCA 14.1 software was used to perform statistical analysis on metabolites. The PCA graph showed that QC clustered, indicating that the mass spectrometry analysis method was stable and effective. The OPLS-DA graph showed that the metabolite profiles between the healthy and disease groups were clearly separated, indicating that the plasma metabolite composition had changed significantly ( Figure 5). In the OPLS-DA model, the R2Y value and Q2 value in the negative ion mode were 0.966 and 0.615, respectively, and the R2Y value and Q2 value in the positive ion mode were 0.959 and 0.65, respectively. Both the R2Y value and Q2 value were greater than 0.5 and close to 1, indicating that the model had good predictive power. By comparing the retention time and mass spectrometry ion pair information, a total of 277 metabolites were identified.
[0060] Compared with healthy controls, 51, 63, and 59 significantly different metabolites were identified in the AS0, AS1, and AS2 groups, respectively (p < 0.05) ( Figure 6 a). Among these metabolites, 34 were present in all AS groups ( Figure 6 b), pathway enrichment was performed on these metabolites, and it was found that they were mainly involved in arginine and proline metabolism, lysine degradation and uric acid cycle. Among them, TMAO and PAGln are metabolites of intestinal microorganisms, which are associated with an increased risk of cardiovascular disease. The present invention found that the levels of plasma TMAO and PAGln were higher in the AS group. In addition, among these 34 differential metabolites, 2-aminoadipic acid, 3-methyluridine, α-ketoglutaric acid, α-N-phenylacetyl-L-glutamine, azelaic acid, β-guanidinopropionic acid, taurine, etc. have been reported to be related to cardiovascular disease; while 3-(1-pyrazolyl)-alanine and 3-aminoisobutyric acid have not been reported to be associated with cardiovascular disease. Example 5, Multi-omics data predicts atherosclerotic disease
[0061] Plasma metabolites (P), gut microbiota (G), and clinical biochemical indicators (C) were used to distinguish healthy controls and patients with atherosclerosis among the subjects.
[0062] The experimental data were statistically analyzed using IBM SPSS Statistics 23 software. The Duncan multiple range test was used to analyze the differences between the groups, and p<0.05 indicated that the differences were statistically significant. A random forest model was established based on the multi-omics data to screen potential biomarkers. The samples were divided into training samples (two-thirds) and test samples (one-third). The random forest algorithm was used to perform automatic feature selection and importance evaluation to identify the most critical features for the classification task. The receiver operating characteristic (ROC) curve is an important indicator for measuring the performance of the classification model. The ROC curve was generated using Monte Carlo cross validation (MCCV) and balanced subsampling. In each MCCV, two-thirds of the samples were used to evaluate the importance of the features to help determine which features had a significant impact on the model performance. Using the important features obtained by the evaluation, multiple classification models containing the important features were attempted to be constructed, and the models were validated on the remaining one-third of the samples. The above process was repeated multiple times, and the performance indicators and confidence intervals of each model were calculated to obtain a comprehensive evaluation of the model performance.
[0063] First, we used single-omics data to predict atherosclerosis, and found that the plasma metabolomics data performed best in predicting atherosclerosis, with an accuracy of >80% and an AUC of 0.8 ( Figure 7 a and c). Test the top five (P5, C5, G5) or ten (P10, C10, G10) important variables in each data set and try to combine them, such as Figure 7 As shown in b, the combination of C5, P5 and G5 can predict health and disease with an accuracy of up to 97.83%, AUC = 0.987 ( Figure 7 b and d). C5 includes body mass index, total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and glomerular filtration rate, P5 includes α-ketoglutarate, cholesterol sulfate, L-glutamate, TMAO and taurine, and G5 includes Alistipes, Collinsella, Clostridium_UCG-014, Streptococcus and Bacteroides, which can be used as candidate biomarkers for predicting atherosclerotic diseases ( Figure 7 e).
[0064] Example 6. Validation of combined biomarkers
[0065] In order to verify the diagnostic ability of the above-mentioned combined biomarkers in predicting the occurrence of atherosclerosis, the present invention measured the content of the above-mentioned 15 biomarker combinations in a validation cohort of 74 participants according to the standards used in the discovery phase, used the model constructed by the discovery cohort, and used Fisher discriminant analysis to discriminate the groups. The prediction results were evaluated by ROC curves. The results showed that these biomarker combinations can better distinguish AS samples from healthy controls, with an AUC of 0.821 ( Figure 8 ). The results showed that the above-constructed biomarker combination can be used to predict the occurrence of atherosclerosis.
[0066] Example 7: Application of combined biomarkers
[0067] The height and weight of the subjects were recorded and the body mass index was calculated. The test samples were selected from stool samples and serum samples. Serum samples were used to measure total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and glomerular filtration rate, α-ketoglutaric acid, cholesterol sulfate, L-glutamic acid, TMAO and taurine; stool samples were used to measure Alistipes, Collinsella, Clostridium_UCG-014, Streptococcus and Bacteroides.
[0068] After obtaining data samples of 15 combined indicators (C5, P5 and G5) in a known cohort (patients who have been previously diagnosed with atherosclerosis), the content of the 15 combined indicators (C5, P5 and G5) in an unknown cohort (personnel to be tested) is measured, and the data is input into the SPSS program to apply the random forest model for discrimination and classification. The patent of this invention provides data samples of 246 known people, which can be used to discriminate and group unknown cohorts. Through this application scenario, the data samples and classification methods provided in the patent can be used to group and classify individuals in an unknown cohort, thereby realizing the assessment and prediction of individual disease risks.
[0069] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A set of biomarkers for detecting atherosclerosis, characterized in that: Including plasma metabolites, intestinal microorganisms and clinical biochemical indicators; the clinical biochemical indicators include total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and glomerular filtration rate; the plasma metabolites include α-ketoglutaric acid, cholesterol sulfate, L-glutamate, TMAO and taurine; the intestinal microorganisms include Alistipes, Collinsella, Clostridium_UCG-014, Streptococcus and Bacteroides.
2. The biomarker according to claim 1, characterized in that The biomarkers were obtained from blood and stool samples of the subjects.
3. The biomarker according to claim 2, characterized in that The blood sample includes plasma or serum.
4. A kit for detecting atherosclerosis, characterized in that: The kit comprises the biomarker according to any one of claims 1 to 3.
5. Use of the biomarker according to any one of claims 1 to 3 in preparing a kit, characterized in that: The kit is used to determine whether a subject suffers from atherosclerosis.
6. The use according to claim 5, characterized in that The kit contains data samples of a known cohort.
7. The use according to claim 6, characterized in that The known cohort is subjects who are determined to have atherosclerosis.
8. The use according to claim 5 or 6, characterized in that: The kit contains reagents for detecting the biomarkers.
9. The use according to any one of claims 5 to 8, characterized in that: The method of determining whether the subject suffers from atherosclerosis comprises the following steps: (1) determining the level of the biomarker in a sample from the subject; (2) Inputting the levels of the biomarkers described in step (1) into a random forest model for discrimination.
10. The use according to claim 9, characterized in that In step (1), the plasma metabolites in the biomarkers are determined by mass spectrometry, and the intestinal microorganisms are determined by sequencing.
